Landmark Trial Finds Drug Aficamten Significantly Improves Function in Hypertrophic Cardiomyopathy

For hundreds of thousands of people living with non-obstructive hypertrophic cardiomyopathy (nHCM), everyday activities like walking up a flight of stairs or carrying groceries can feel like running a marathon. Until now, patients with this genetic heart condition have had no approved medical therapies to treat the root mechanical cause of their debilitating fatigue and breathlessness.[6]

That landscape shifted dramatically today. Full results from a landmark Phase 3 clinical trial, presented at the European Society of Cardiology (ESC) Congress in Munich and published in the New England Journal of Medicine, revealed that an experimental drug called aficamten significantly improves both exercise capacity and daily symptoms for these patients.[2]

The trial, known as ACACIA-HCM, represents a watershed moment in cardiovascular medicine. It is the first time a therapy has successfully demonstrated clinically meaningful benefits for the non-obstructive form of hypertrophic cardiomyopathy, a condition where the heart muscle becomes abnormally thick and stiff, impairing its ability to relax and fill with blood.[1][5]

"Based on this trial, this is the first-ever successful therapy for non-obstructive hypertrophic cardiomyopathy," said Dr. Ahmad Masri, the trial's lead investigator and a cardiologist at Oregon Health & Science University. "These results are highly encouraging for patients with this condition and for cardiologists who struggle to help them."[4]

To understand why aficamten is so effective, it helps to look at the mechanics of the disease. Hypertrophic cardiomyopathy affects an estimated 1 in 350 people worldwide. In about half of these cases, the thickened heart muscle physically obstructs blood flow out of the heart—a condition known as obstructive HCM.[4]

The other half, however, have the non-obstructive form. Their blood flow isn't physically blocked, but the heart muscle is hypercontractile—meaning it squeezes too hard and fails to relax properly between beats. This chronic stiffness forces the heart to work overtime, leading to severe fatigue, shortness of breath, and a drastically reduced quality of life.[6]

Aficamten, developed by the biopharmaceutical company Cytokinetics, belongs to a new class of drugs called cardiac myosin inhibitors. It works by targeting the specific proteins in the heart muscle responsible for contraction. By slightly dampening this hypercontractility, aficamten allows the heart muscle to relax, fill with blood more efficiently, and operate with less strain.[1][5]

The ACACIA-HCM trial enrolled 517 adults across 182 international sites, randomizing them to receive either a daily pill of aficamten or a placebo for up to 72 weeks. The researchers meticulously tracked the patients' progress using both subjective symptom questionnaires and objective exercise tests.[2][3]

The results at the 36-week mark were striking. Patients taking aficamten showed a statistically significant improvement in their Kansas City Cardiomyopathy Questionnaire (KCCQ) scores, a standard metric for heart failure symptoms. Their scores jumped by 11.4 points, compared to an 8.4-point increase in the placebo group.[2][5]

More importantly, the drug objectively improved physical function. During cardiopulmonary exercise testing, patients on aficamten increased their peak oxygen uptake (pVO2)—a gold-standard measure of cardiovascular fitness—by 0.64 ml/kg/min. In contrast, the placebo group saw their capacity slightly decline by 0.03 ml/kg/min.[2]

"Traditionally, we have placed more weight on peak oxygen consumption because it is a very hard endpoint to move," Dr. Masri explained in discussions surrounding the data. Most standard heart failure therapies fail to improve pVO2, even when they successfully reduce mortality and hospitalizations, making aficamten's impact particularly notable.[2][4]

The benefits extended beyond the primary endpoints. Patients taking aficamten also showed significant improvements in cardiac biomarkers, such as NT-proBNP, which indicates reduced strain on the heart wall. Furthermore, 53% of patients on the drug demonstrated a clinical response across three or more outcome measures, compared to just 13% on placebo.[5]

While the efficacy data is highly promising, the trial also provided crucial insights into the drug's safety profile. Because aficamten intentionally reduces the heart's pumping force, there is a risk of lowering the left ventricular ejection fraction (LVEF) too much.[2][6]

In the trial, 10.5% of patients taking aficamten experienced a drop in LVEF below 50%, compared to just 0.8% in the placebo group. However, researchers noted that these drops were safely managed and reversed by adjusting the patients' dosage, underscoring the need for careful monitoring if the drug reaches the clinic.[2]

Patients in the aficamten group also reported a higher rate of serious adverse events (20.2%) compared to the placebo group (14.7%). This highlights the importance of a nuanced conversation between patients and their cardiologists about balancing the profound symptom relief against the need for ongoing medical supervision.[2][6]

For Cytokinetics, the ACACIA-HCM results mark a triumphant milestone. The company, which spent 27 years securing its first drug approval, is now poised to rapidly expand its cardiovascular portfolio. Cytokinetics plans to submit a Supplemental New Drug Application to the FDA in the fourth quarter of 2026.[1][5]

For patients currently managing nHCM, these findings offer a clear reason for optimism, but not an immediate prescription. The drug still requires regulatory review, meaning it won't be available at the pharmacy tomorrow.[6]

In the meantime, patients should discuss these upcoming advancements with their cardiologists to understand if they might be candidates for cardiac myosin inhibitors once approved, and ensure their current symptom management plan is optimized. Instead of relying indefinitely on off-label medications that only mask symptoms, patients may soon have a targeted therapy that addresses the underlying mechanical flaw in their hearts.[6]